Immuron Ltd. IMRN

What this company does

Immuron is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases. Immuron Limited was incorporated as an Australian Public Company, Limited by Shares under the name Anadis Limited (and changed its name to Immuron Limited in December 2008) in Victoria, Australia under the laws of the Commonwealth of Australia in 1994 and our ordinary shares have been listed on the ASX since April 30, 1999. We are a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on the development and commercialization of a novel class of specifically targeted polyclonal antibodies that we believe can address significant unmet medical needs. Our principal executive office is located at Level 3, 62 Lygon Street, Carlton South, Victoria, Australia 3053 and our telephone number is +61 (0)3 8892 4854. We currently market our flagship commercial product Travelan®, and Protectyn® in Australia, where both products are listed medicines on the Australian Register for Therapeutic Goods.

Written from the business description in Immuron Limited's annual report to the U.S. Securities and Exchange Commission, filed 25 September 2025. Every sentence was checked against that document before publication.